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Abstract 
Purpose: To investigate the pharmacokinetic mechanism of interaction between magnolol and piperine 
when co-administered to rats. 
Methods: The rats were divided into five groups as follows: magnolol group (625 mg/kg); low dose of 
piperine group (20 mg/kg); high dose of piperine group (40 mg/kg); low dose of piperine + magnolol 
group; or high dose of piperine + magnolol group. Plasma samples were collected at regular time 
intervals after administration of a single dose of magnolol (625 mg/kg, p.o.) alone or piperine (20 or 40 
mg/kg, p.o.) in the presence or absence of magnolol (625 mg/kg, p.o.). The concentrations of magnolol 
and piperine in plasma were measured by a validated high performance liquid chromatography (HPLC) 
method.  
Results: Compared with control, the groups given magnolol alone, concomitant administration of 
piperine and magnolol resulted in significant decrease (p < 0.01) in the AUC and Cmax of magnolol. 
Interestingly, compared with administration of piperine alone (20 mg/kg), co-administration with 
magnolol did not significantly (p > 0.05) alter the pharmacokinetic parameters of piperine. However, at 
high dose (40 mg/kg) of piperine, Cmax of piperine significantly decreased from 4.30 ± 1.47 to 2.50 ± 
0.78 µg/mL (p < 0.05).  
Conclusion: Co-administration of magnolol and piperine decreases plasma concentration of either drug 
in rats, suggesting that concurrent use of magnolol with piperine or piperine-containing diets would 
require close monitoring for potential interactions. 
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Magnolol a substrate for P-glycoprotein (P-gp), 
shown in Figure 1a, is one of the major 
compounds contained in the bark of Magnolia 
officinalis, which has been widely prescribed for 
the treatment of gastrointestinal diseases [1]. 
Various studies have shown that magnolol has a 
variety of pharmacological activities such as 
cardio-protection, anti-inflammation, anti-
depression, anti-carcinogenic and anti-bacterial 
effect [2-4]. However, the oral bioavailability of 
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magnolol, is reported to be only 5 % due to 
extensive first-pass metabolism and low 
absorption [5]. Efflux transporters such as P-gp 
are critical functional proteins in drug metabolism 
and transport, and have been shown to limit oral 
drug absorption and tissue distribution [6]. It is 
speculated that the concomitant use with 
compounds that influence the P-gp may change 
its pharmacokinetics. 
 
Piperine (1-peperoyl peperidine, Figure 1b), a 
major active ingredient of black pepper (Piper 
nigrum Linn.) and long pepper (Piper longum 
Linn.), has been shown to have fundamental 
effects on P-gp and many enzyme systems, 
leading to biotransformative effects including 
detoxification and enhancement of the absorption 
and bioavailability of herbal and conventional 
drugs. At present, piperine has been found to 
increase the plasma concentrations of various 
structurally and therapeutically diverse drugs, 
such as theophylline, phenytoin, rifampin, and 
propranolol [7], possibly due to the inhibition of 
metabolic pathways and /or P-gp-mediated drug 
efflux.  
 
In traditional Chinese medicine, magnolia bark 
was commonly prescribed with long pepper in 
Chinese formula such as “Houpu-biba Wan” in 
the therapy of gastrointestinal disorders. Due to 
the common use of magnolol and piperine in the 
digestive system as dietary supplements or in 
medicinal forms, the prediction of their possible 
pharmacokinetic interaction would help to 
provide beneficial information and facilitate their 
safe application. Therefore, the purpose of this 
study was to investigate whether and how 
peperine affected the pharmacokinetics of 
magnolol in rats after oral administration at 
different dosages, and estimate their 
concentrations in plasma by RP-HPLC method. 
 
 





Chemicals and reagents 
 
Piperine with purity > 99 % was purchased from 
Xian Kaicheng Biological Technology Co., Ltd, 
Xian, China. Magnolol with purity > 99 % was 
obtained from Guangzhou Hechengsanxian 
biological technology Co., Ltd, Guangzhou, 
China. Osthole (C15H16O3), used as internal 
standard (IS), was obtained from National 
Institute for the Control of Pharmaceutical and 
Biological Products. HPLC-grade methanol was 
purchased from Merck KGaA (Darmstadt, 
Germany), and acetic acid from Guangdong 
Guanghua Chemical Factory Co., Ltd. 
(Guangdong, China). Ultrapure water was 
prepared using a Milli-Q gradient water 
purification system (Millipore, Bedford, MA, 
USA). All other regents and chemicals used in 
this study were of analytical grade. 
 
Instrumentation and conditions 
 
Shimadzu HPLC system (Kyoto, Japan) 
consisting of pump (LC-20AD), UV detector 
(SPD-20A) and LC solution chromatographic 
workstation was used for all analyses. The 
chromatographic resolutions of piperine and 
magnolol were carried out on a Diamonsil C18 
column (particle size, 5 μm, 250 × 4.6 mm, 
Dikma, China) with the isocratic mobile phase 
consisting of methanol and 0.1 % acetic acid in 
water (78:22, v/v) at a flow rate of 1.0 mL/min. An 
aliquot of 10 μL blood sample was injected for 
HPLC analysis, and the UV detection 
wavelengths were set at 294 nm and 340 nm for 




Male Sprague-Dawley rats (200 ± 20 g) were 
purchased from the Laboratory Animal Center, 
Guangzhou University of Chinese Medicine 
(Guangzhou, China). All experimental protocols 
involving animals and their care were approved 
(ref. no. SYXK (YUE) 2008-0085) by the Animal 
Experimental Ethics Committee of Guangzhou 
University of Chinese Medicine (Guangzhou, 
China), and the experimental protocols followed 
the “Guide for the Care and Use of Laboratory 
Animals” [8].  
 
Rats housed in the standard rat cages were kept 
at ambient temperature with a relative humidity of 
50 ± 10 % and 12 h light/dark cycle. The animals 
were used for studies after one week 
acclimatization with free access to water and 
standard rat chow. 
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Experimental design and pharmacokinetic 
studies 
 
All rats were fasted overnight but supplied with 
water ad libitum prior to the pharmacokinetic 
investigation. Rats were randomly divided into 
the following five groups (n = 6): group 1: 
magnolol (625 mg/kg), group 2: low dose of 
piperine (20 mg/kg), group 3: high dose of 
piperine (40 mg/kg), group 4: low dose of 
piperine (20 mg/kg) + magnolol (625 mg/kg), and 
group 5: high dose of piperine (40 mg/kg) + 
magnolol (625 mg/kg).  
 
Both magnolol and piperine were prepared as 
suspensions in 0.5 % carboxymethyl cellulose 
sodium salt (CMC-Na) aqueous solution just 
before each experiment. The dose levels of 
piperine have been selected based on our 
previous pharmacokinetic studies [9]. The dose 
of magnolol was chosen based on the clinical 
use and our preliminary experiment.  
 
Blood samples were collected from the suborbital 
vein into heparinized Eppendorf microtubes, 
before administration and at 0.25, 0.5, 0.75, 1, 
1.5, 2, 4, 6, 8, 12 and 24 h after administration. 
After collection, the plasma samples were 
immediately separated by centrifugation at 
10,000 rpm for 10 min and stored at -20 °C for 
subsequent analysis. 
 
Preparation of plasma samples 
 
To a 100 μL aliquot of blood plasma sample in a 
2 mL Eppendorf microtube, 50 μL of internal 
standard (9.48 μg/mL) was added. The samples 
were vortexed for 2 min and 450 μL of methanol 
was added. The mixture was vortex-mixed for 3 
min. After centrifugation at 10,000 rpm for 5 min, 
the supernatant was separated and evaporated. 
The resulting dried residue was reconstituted in 
200 μL of methanol and then centrifuged at 2, 
000 rpm for 10 min. The supernatant was 
isolated for HPLC analysis. 
 
Preparation of standard solution 
 
Individual stock solutions of magnolol (100 
μg/mL) and piperine (100 μg/mL) were prepared 
in methanol. A stock solution of IS was prepared 
by dissolving osthole in methanol to a final 
concentration of 9.48 μg/mL. A serious of 
working solutions were obtained by further 
diluting the stock solutions. Calibration standards 
were prepared by spiking the appropriate 
amounts of standard solutions into blank plasma 
to obtain final concentrations levels of 0.8, 1.0, 
2.5, 5.0, 10.0, 20.0 μg/mL and 0.1, 0.5, 1.0, 2.5, 
5.0, 10.0 μg/mLfor magnolol and piperine 
respectively. The quality control (QC) samples 
were similarly prepared at concentrations of 0.8, 
2.5, 10 μg/mL and 0.5, 2.5, 5.0 μg/mL for low, 
medium and high concentration QC samples 
magnolol and piperine, respectively. All working 
solutions were stored at -4 °C. 
 
Method validation  
 
The method was validated for specificity, 
linearity, accuracy, precision, recovery and 
stability, according to the principles of the US 
Food and Drug Administration (2001) industry 




The specificity was evaluated by comparing 
chromatograms of blank plasma and plasma 
spiked with the standard solutions. 
 
Linearity of calibration curves and lower 
limits of quantification (LLOQ) 
 
The calibration curves of magnolol and piperine 
were performed with six concentrations. Peak-
area ratios of the analyte to the IS were 
calculated and the calibration curves were 
established by fitting the ratio to the 
corresponding concentrations using regression 
analysis with 1/X2 weighting. LLOQ was defined 
as the lowest concentration on the calibration 
curve at which the signal-to-noise ratio was 
above 10 with an acceptable accuracy within ± 
10 % and the precision below 15 %. 
 
Accuracy and precision  
 
Intra- and inter-day precisions were determined 
by assessing the measured results of the QC 
samples at low, medium, and high 
concentrations. Precision was evaluated as the 
relative standard deviation (RSD), while accuracy 
(%) was evaluated by the percentage difference 
between the mean measured concentrations and 
the spiked concentrations, expressed as the 




Extraction recoveries were determined by 
comparing the ratio of analyte peak areas of the 
extracted QC samples with those of un-extracted 
standard solutions at the same nominal 
concentrations. The matrix effects were 
measured by comparing the peak areas of blank 
plasma extracts spikes with analytes with those 
of pure standard solution containing equivalent 
amounts of the analytes.  
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Stability was checked by comparing the 
measured results with those of the freshly 
prepared samples of the same concentration 
under different storage conditions: short-term 
stability at room temperature for 4 h; long-term 
stability at -20 °C for 7 days; after three freeze-




Pharmacokinetic analysis was performed based 
on a non-compartmental description of the data 
obtained. Drug and Statistics software (version 
3.1.5, BioGuider Co., Shanghai, China) was used 
to calculate the model-independent parameters, 
such as the area under plasma concentration-
time curve (AUC), volume of distribution (Vd), 
clearance (CL) and half-life (t1/2). In addition, the 
maximum plasma concentration (Cmax) and the 
time to reach the maximum plasma concentration 





All means were presented with their standard 
deviation (SD). Comparisons of the 
pharmacokinetic parameters were analyzed by 
the two-tailed unpaired Student’s t-test, and p < 
0.05 was considered statistically significant 
(SPSS statistical software package, version 17.0, 




HPLC analysis  
 
To obtain a rapid and simple HPLC-UV method 
for simultaneous determination of magnolol and 
piperine in the rat plasma, the chromatographic 
conditions were optimized and validated. The 
representative chromatograms of plasma spiked 
with the standard solutions were shown in Figure 
2. The retention time for magnolol, piperine and 
internal standard (IS) were approximately 20.1, 
10.5 and 12.8 min, respectively. Under the 
optimized conditions, no significant endogenous 
interference was observed. 
 
Method validation  
 
The calibration curve from magnolol was found to 
be linear over the concentration range of 0.8 to 
20 μg/mL in rat plasma with the linear regression 
equation Y=0.0775X-0.0295 (R2 = 0.9998). The 
lower limit of quantification (LLOQ) was 0.8 
μg/mL. The intra- and inter-day precision of 
magnolol was < 10 %, and accuracy ranged from 
-3.3 to 8.9 %. 
 
The standard curve developed to quantify the 
piperine concentration in the rat blood was of 
good linearity (R2 = 0.9988) over the 
concentration range of 0.1 to 10 μg/mL. The 
intra- and inter-day precision of piperine was < 
12 %, and the accuracy was between - 4.6 and 
9.3 %, respectively.  
 
The mean extraction recoveries at three QC 
levels were 91.33 ± 5.11, 98.07 ± 4.95 and 94.91 
± 4.02 % for magnolol, and 90.14 ± 4.57, 96.16 ± 
4.21 and 93.66 ± 3.96 % for piperine, 
respectively. No significant matrix effect for 
magnolol, piperine and IS was observed, which 
indicated that the co-eluting substance did not 
influence the ionization of the analytes and IS. 
No significant changes in serum concentrations 
of magnolol and piperine were detected after 
three freezing and thawing cycles, as well as at 




Figure 2: Typical chromatograms of rat plasma sample after simultaneous oral administration of magnolol and 
piperine 
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The results indicated that the proposed method 
was validated to guarantee a reliable 
determination of magnolol and piperine in rat 
plasma and was applicable to the 
pharmacokinetic study on magnolol and piperine 
in rat plasma. 
 
Effect of piperine on the oral pharmacokine-
tics of magnolol 
 
The mean plasma concentration-time plots of 
magnolol following oral administration in the 
presence or absence of piperine are depicted in 
Figure 3, and the mean pharmacokinetic 
parameters of magnolol are summarized in Table 
1. Compared with the control group given 
magnolol alone, the AUC of magnolol was 
significantly decreased from 105.42 ± 21.70 
µg/mL*h in the control group to 36.72 ± 12.62 
and 39.36 ± 17.67 µg/mL*h (p < 0.01) for 20 and 
40 mg/kg piperine treatment group, respectively. 
Similarly, Cmax of magnolol significantly declined 
to 58.91 and 71.10 % (both p < 0.01) via the 
concomitant use of 20 and 40 mg/kg piperine, 
respectively, as compared with the control group. 
In contrast, CL of magnolol was significantly 
increased from 5.98 ± 1.67 L/h/kg in the control 
group to 17.62 ± 4.58 (p < 0.01) and 17.39 ± 
6.18 L/h/kg (p < 0.05) in the 20 and 40 mg/kg 
piperine treatment group, respectively. 
Meanwhile, t1/2 of magnolol was similar in the 
presence or absence of piperine. When 
compared with control group, magnolol blood 
concentrations of the rats pre-treated with 20 
mg/kg piperine, however, were not significantly 





Figure 3: Plasma concentration-time profiles of magnolol after oral administration of magnolol to rats in the 
presence and absence of piperine. The data are expressed as mean ± SD, n = 6. (●) control (magnolol alone); 
(∆) combined with 20 mg/kg of piperine; (▼) combined with 40 mg/kg of piperine 
  
Table 1: Pharmacokinetic parameters for magnolol in rats after oral administration in the presence and absence 
of piperine (mean ± SD, n = 6) 
 
Parameter Magnolol alone  With piperine 20 mg/kg 40 mg/kg 
AUC0-t (µg/mL*h) 100.74 ± 19.11 32.92 ± 11.13** 36.77 ± 14.45** 
AUC0−∞ (µg/mL*h) 105.42 ± 21.70 36.72 ± 12.62** 39.36 ± 17.67** 
Cmax (µg/mL) 9.03 ± 1.26 5.32 ± 1.41** 6.42 ± 0.80** 
Tmax (h) 5.67 ± 1.97 1.75 ± 0.42** 1.15 ± 0.60** 
Vd (L/kg) 27.14 ± 15.67 59.70 ± 18.34** 62.129 ± 28.08* 
CL (L/h/kg) 5.98 ± 1.67 17.62 ± 4.58** 17.39 ± 6.18* 
t1/2 (h) 4.10 ± 2.19 2.99 ± 1.60 1.94 ± 0.42 
Note: Asterisks indicate significant differences: *p <0.05 and **p <0.01 versus control group given magnolol 
alone 
 
Chen et al 
Trop J Pharm Res, March 2016; 15(3): 636  
 
Effect of magnolol on oral pharmacokinetics 
of piperine 
 
The mean plasma concentration-time profiles of 
piperine (20 and 40 mg/kg) administered alone or 
in combination with 625 mg/kg magnolol are 
shown in Figures 4 and 5, and the 
pharmacokinetic parameters were summarized in 
Table 2. As shown in Table 2, co-administration 
of magnolol did not significantly alter the 
pharmacokinetic parameters of piperine when 
compared with the administration of piperine 
alone (20 mg/kg). However, at high dose of 
piperine (40 mg/kg), the Cmax of piperine was 
significantly decreased from 4.30 ± 1.47 µg/mL 
to 2.50 ± 0.78 µg/mL (p < 0.05). Nevertheless, 
there was no significant difference in the AUC 
and t1/2 of piperine in the plasma when piperine 




Figure 4: Plasma concentration-time profiles of piperine after oral administration of 20 mg/kg of piperine to rats in 
the presence and absence of magnolol. The data are expressed as mean ± SD, (n = 6). (●) piperine with CMC; 
(◊) piperine combined with magnolol 
 
 
Figure 5: Plasma concentration-time profiles of piperine after oral administration of 40 mg/kg of piperine to rats in 
the presence and absence of magnolol. The data are expressed as mean ± SD, (n = 6). (▼) piperine with CMC; 
(∆) piperine combined with magnolol 
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Table 2: Pharmacokinetic parameters of piperine after oral administration of piperine 20 and 40 mg/kg to rats in 
the presence and absence of 625 mg/kg magnolol (mean ± SD, n = 6) 
 
Parameter Piperine (20 mg/kg) Piperine (40 mg/kg) Alone + Magnolol Alone + magnolol 
AUC0-t (µg/mL*h) 14.66 ± 5.91 17.53 ± 6.018 44.89 ± 17.87 30.11 ± 10.18 
AUC0−∞ (µg/mL*h) 14.66 ± 5.91 21.19 ± 7.71 50.56 ± 21.63 36.42 ± 7.52 
Cmax (µg/mL) 1.79 ± 0.22 1.60 ± 0.62 4.30 ± 1.47 2.50 ± 0.78* 
Tmax (h) 2.42 ± 1.28 2.70 ± 1.20 5.00 ± 1.10 6.00 ± 3.10 
Vd (L/kg) 3.37 ± 1.48 14.88 ± 8.95 7.23 ± 1.79 7.77 ± 2.50 
CL (L/h/kg) 1.53 ± 0.51 1.04 ± 0.34 0.98 ± 0.55 1.14 ± 0.23 
t1/2 (h) 1.80 ± 0.17 1.92 ± 1.53 7.08 ± 2.44 6.16 ± 3.23 




P-glycoprotein (P-gp) as the drug export pump, is 
important for the absorption, distribution and 
excretion of drug [11,12]. Owing to various health 
promoting effects, dietary supplements as 
alternative medicines are becoming increasingly 
popular, leading to an increased incidence of 
patients taking the prescribed medicine with 
dietary supplements. Furthermore, given that 
many of the dietary supplements and 
phytochemicals can modulate the activity of P-gp 
and drug metabolizing enzymes, there should be 
more attention given to potential drug 
interactions with dietary supplements. Among 
dietary products, black pepper and long pepper 
are one of the most common culinary spices and 
nutrient enhancers. Piperine, a major active 
component of black pepper and long pepper, has 
been reported to enhance drug bioavailability 
and interactions by altering the pharmacokinetics 
[13]. In view of popular use of magnolol and 
piperine for the promotion of digestive function in 
dietaries and medicines, their concomitant intake 
should be paid attention to. In the present study, 
possible pharmacokinetic interaction was 
comparatively investigated following the 
concurrent administration of magnolol and 
piperine to rats. 
 
Studies have shown that piperine inhibited P-gp-
mediated drug efflux during intestinal absorption 
to increase the plasma concentrations of some 
drugs, such as theophylline, phenytoin and 
refampin [14]. However, the results in the present 
study were opposite. As shown in Table 1, the 
Cmax and AUC0−∞ were markedly decreased by 
co-administration of piperine at dosages of 20 
and 40 mg/kg, indicating that the oral 
bioavailability of magnolol in rats was 
significantly reduced by concurrent intake of 
piperine. Pharmacokinetic study of magnolol 
revealed that the absorption of magnolol was 
apparently hampered by piperine, of which both 
dosages of piperine exerted comparable effects. 
There was no significant difference between the 
two treatment groups (20 and 40 mg/mL), 
implying that the interaction effect was not dose-
dependent.  
 
Co-administration of high dose of piperine (40 
mg/kg) with magnolol significantly decreased the 
plasma levels of piperine in the absorption phase 
and the Cmax. Although the AUC was reduced at 
40 mg/kg piperine group, the difference was not 
statistically significant. Compared to the low dose 
piperine group, magnolol reduced the Cmax and 
delayed the Tmax of piperine. However, the 
difference was not statistically significant (p > 
0.05). These results may be associated with the 
effect of magnolol on liver microsomal CYP450. 
It has been reported that magnolol exert 
significant inhibitory effects on the activities of 
CYP1A2 and CYP2E1 and relatively less effect 
on CYP3A4 [15]. In addition, our studies have 
found that magnolol did not affect the Tmax value 
of piperine. These observations imply that 
magnolol might have little effect on the peristalsis 
of the gastrointestinal tract or gastric emptying 
time. However, the exact mechanisms underlying 




Co-administration of magnolol and piperine 
decreases the plasma concentration of either 
drug in rats. The findings suggest that concurrent 
use of magnolol and piperine or piperine-
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